NextCell Pharma AB participates in BIO-Europe 2024 and welcomes a visit from Minister Ebba Busch
NextCell Pharma AB* proudly announces its participation in BIO-Europe 2024, one of Europe’s most significant partnering conferences in biotechnology and pharmaceutical development. The event will be held at Stockholmsmässan from November 4-6, and is expected to gather over 5,000 leading professionals from around the world.
During BIO-Europe, NextCell will be an active part of the Swedish pavilion organized by Business Sweden, providing a unique opportunity to showcase NextCell's advancements and contributions in cell therapy and precision medicine. The company also looks forward to participating in several partnering meetings during the conference, facilitating strategic discussions and collaboration opportunities with international stakeholders.
As part of the Swedish business initiative at BIO-Europe, NextCell is honored to welcome Sweden’s Minister for Energy, Business and Industry and Deputy Prime Minister, Ebba Busch, to their booth in the Swedish pavilion. The minister's visit is an important recognition for NextCell and other Swedish companies leading the way in biotechnology. Busch's presence underscores the government’s commitment to strengthening the international competitiveness of Swedish biotech companies and promoting innovation for a sustainable future.
"Participating in BIO-Europe and being part of the Swedish pavilion is a strategically important opportunity for NextCell. We look forward to fruitful discussions and expanding our global network," says Mathias Svahn, CEO of NextCell Pharma AB. "It is also an honor to welcome Ebba Busch, which highlights the significance of the biotech sector for Sweden and the future of healthcare."
BIO-Europe 2024 is expected to be a highly engaging event with a focus on innovation, partnerships, and growth within biotechnology. NextCell Pharma AB looks forward to representing Swedish biotech and continuing efforts for better global health through groundbreaking cell therapies and treatments.
* NextCell Pharma AB, "NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL
For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com
Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma
For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se
Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva
Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser.
About NextCell Pharma AB
NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes, ProTrans is used in two clinical trials for, in Örebro and in Montreal, Canada. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology, and 100% of Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell is also a 100% owner of the daughter company, QVance which will offer quality control analytics for advanced therapy developers.